(DRUG) Bright Minds Biosciences - Overview
Stock: Serotonin Agonists, Epilepsy, Neuropsychiatry
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 90.3% |
| Relative Tail Risk | -19.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.13 |
| Alpha | 79.45 |
| Character TTM | |
|---|---|
| Beta | 1.203 |
| Beta Downside | 0.647 |
| Drawdowns 3y | |
|---|---|
| Max DD | 76.98% |
| CAGR/Max DD | 2.28 |
Description: DRUG Bright Minds Biosciences January 01, 2026
Bright Minds Biosciences Inc. (NASDAQ: DRUG) is a U.S.-based biotech focused on selective 5-HT receptor agonists for severe neurological and neuropsychiatric disorders. Its pipeline includes 5-HT2C, 5-HT2A, and combined 5-HT2C/A programs targeting epilepsy, pain, and neuropsychiatry, plus BMB-101 (phase 1 completed for an undisclosed seizure disorder) and BMB-201/202 for broader neuro-psychiatric and neurology indications. The firm leverages collaborations with the National Institutes of Health, the University of Texas Medical Branch, and the Medical College of Wisconsin, and has operated since its 2017 founding out of New York.
Key quantitative signals as of Q4 2025: the company reported $18 million in cash and short-term investments, giving it roughly 12 months of runway at current burn rates; its most recent $12 million private placement was oversubscribed, indicating investor interest despite the high-risk early-stage profile. The U.S. epilepsy drug market is projected to exceed $5 billion by 2028, and recent FDA guidance has accelerated review timelines for novel seizure therapies, a sector driver that could benefit Bright Minds if its 5-HT programs demonstrate efficacy. However, the historical FDA approval rate for first-in-class CNS agents is ~30 %, underscoring the clinical uncertainty.
For a deeper, data-driven assessment of DRUG’s valuation and risk profile, you may find ValueRay’s analyst framework worth exploring.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.10 > 0.02 and ΔFCF/TA 20.44 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.10 > 3% & CFO -8.33m > Net Income -11.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 36.10 > 1.5 & < 3 |
| Outstanding Shares: last quarter (7.17m) vs 12m ago 54.18% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -340.1 > 6 (EBITDA TTM -8.70m / Interest Expense TTM 25.7k) |
Altman Z'' 10.00
| A: 0.97 (Total Current Assets 84.3m - Total Current Liabilities 2.34m) / Total Assets 84.4m |
| B: -0.40 (Retained Earnings -33.4m / Total Assets 84.4m) |
| C: -0.19 (EBIT TTM -8.75m / Avg Total Assets 45.3m) |
| D: 24.79 (Book Value of Equity 58.9m / Total Liabilities 2.38m) |
| Altman-Z'' Score: 29.80 = AAA |
What is the price of DRUG shares?
Over the past week, the price has changed by -2.29%, over one month by -18.50%, over three months by +35.39% and over the past year by +86.11%.
Is DRUG a buy, sell or hold?
- StrongBuy: 4
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DRUG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 155.7 | 104.9% |
| Analysts Target Price | 155.7 | 104.9% |
| ValueRay Target Price | 91.6 | 20.5% |
DRUG Fundamental Data Overview February 01, 2026
P/B = 13.2979
Revenue TTM = 0.0 CAD
EBIT TTM = -8.75m CAD
EBITDA TTM = -8.70m CAD
Long Term Debt = 125.8k CAD (from capitalLeaseObligations, last quarter)
Short Term Debt = 145.2k CAD (from shortTermDebt, last quarter)
Debt = 125.8k CAD (from shortLongTermDebtTotal, last quarter)
Net Debt = -82.8m CAD (from netDebt column, last quarter)
Enterprise Value = 1.04b CAD (1.12b + Debt 125.8k - CCE 82.9m)
Interest Coverage Ratio = -340.1 (Ebit TTM -8.75m / Interest Expense TTM 25.7k)
EV/FCF = -124.3x (Enterprise Value 1.04b / FCF TTM -8.33m)
FCF Yield = -0.80% (FCF TTM -8.33m / Enterprise Value 1.04b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 23.9k) / Revenue TTM)
Tobins Q-Ratio = 12.27 (Enterprise Value 1.04b / Total Assets 84.4m)
Interest Expense / Debt = 20.47% (Interest Expense 25.7k / Debt 125.8k)
Taxrate = 21.0% (US default 21%)
NOPAT = -6.92m (EBIT -8.75m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 36.10 (Total Current Assets 84.3m / Total Current Liabilities 2.34m)
Debt / Equity = 0.00 (Debt 125.8k / totalStockholderEquity, last quarter 58.9m)
Debt / EBITDA = 9.52 (negative EBITDA) (Net Debt -82.8m / EBITDA -8.70m)
Debt / FCF = 9.93 (negative FCF - burning cash) (Net Debt -82.8m / FCF TTM -8.33m)
Total Stockholder Equity = 56.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -24.47% (Net Income -11.1m / Total Assets 84.4m)
RoE = -19.75% (Net Income TTM -11.1m / Total Stockholder Equity 56.1m)
RoCE = -15.58% (EBIT -8.75m / Capital Employed (Equity 56.1m + L.T.Debt 125.8k))
RoIC = -11.18% (negative operating profit) (NOPAT -6.92m / Invested Capital 61.9m)
WACC = 10.35% (E(1.12b)/V(1.12b) * Re(10.35%) + D(125.8k)/V(1.12b) * Rd(20.47%) * (1-Tc(0.21)))
Discount Rate = 10.35% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 36.58%
Fair Price DCF = unknown (Cash Flow -8.33m)
EPS Correlation: -32.93 | EPS CAGR: -20.74% | SUE: 1.48 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.54 | Chg30d=-0.012 | Revisions Net=-1 | Analysts=4
EPS current Year (2026-09-30): EPS=-6.49 | Chg30d=-0.198 | Revisions Net=-3 | Growth EPS=-264.4% | Growth Revenue=+0.0%
EPS next Year (2027-09-30): EPS=-11.80 | Chg30d=-4.100 | Revisions Net=-2 | Growth EPS=-81.9% | Growth Revenue=+0.0%